Top Banner
Malaria and its conquering Joel G. Breman, MD, DTPH Fogarty International Center National Institutes of Health Tropical Infectious Diseases Workshop Oswaldo Cruz Foundation (FIOCRUZ) Rio de Janeiro, Brazil 28 April–1 May 2003
34
Welcome message from author
This document is posted to help you gain knowledge. Please leave a comment to let me know what you think about it! Share it to your friends and learn new things together.
Transcript
Page 1: 18581

Malaria and its conquering

Joel G. Breman, MD, DTPH

Fogarty International Center

National Institutes of Health

Tropical Infectious Diseases Workshop

Oswaldo Cruz Foundation (FIOCRUZ)

Rio de Janeiro, Brazil

28 April–1 May 2003

Page 2: 18581

Conquering Malaria

• Ecology and burden

• Interventions

• Successes

• Economics

• Research questions

• Controversies

Page 3: 18581

Ecology and Burden

Page 4: 18581

Malaria and Ecology and Burden

Intrinsic and Extrinsic Factors

Controland prevention

measuresHuman

Parasite Mosquito

Social, behavioral, economic and

political factors

Environmental conditions

Page 5: 18581

Malaria Ecology and BurdenClinical Manifestations

Infected Mosquito

Infected Human

Chronic effects

Anemia

Neurologic/ cognitive

Developmental

Impaired growth and development

Malnutrition

Acute febrile illness

Severe illness

Hypoglycemia

Anemia

Cerebral malaria

DeathRespiratory distress

Pregnancy

Fetus

MaternalAcute illness

AnemiaImpaired productivity

Low birth weight Infantmortality

Page 6: 18581
Page 7: 18581

Mendis K, Sina B J, Marchesini P, Carter R (2001) The neglected burden of P.vivax malaria. American Journal of Tropical Medicine and Hygiene 64; Supplement titled "The Intolerable Burden of Malaria: A New Look at the Numbers" 1-106.

Global distribution of Plasmodium vivax

maximum distribution 19th century (pink) late 20th century (purple)

Page 8: 18581

MARA/ARMA Model of Malaria Transmission, 2003

Page 9: 18581

Deaths and Malaria-related Deaths (1000s), 2000

Population All deaths (%)

Malaria Deaths (%)

Malaria/

total (%)

World 6,122,210 56,554 1,124 2.0

Africa 655,476 10,681 (18.9) 963 (85.7) 9.0

Americas 837,967 5,911 (10.5) 1 (-) 0.02

East Med. 493,091 4,156 (7.3) 55 (4.9) 1.3

Europe 874,178 9,703 (17.2) 0 -

SE Asia 1,559,810 14,467 (25.6) 95 (8.5) 0.7

West Pacific

1,701,689 11,636 (20.6) 10 (0.9) 0

Page 10: 18581

Disability–adjusted Life Years (DALYs, 1000s),All Cause and Malaria-related, 2002

Population

DALYs from

all deaths (%)

DALYs from

malaria

deaths (%)

DALYs from malaria

/total (%)

World 6,122,210 1,467,257 42,280 2.9

Africa 655,476 357,884 (24.4) 36,012 (85.2) 10.1

Americas 837,967 145,217 (9.9) 108 (0.2) 0.07

East Med. 493,091 136,221 (9.3) 2,050 (4.8) 1.5

Europe 874,178 151,223 (10.3) 20 (0.04) 0.01

SE Asia 1,559,810 418,844 (28.5) 3,680 (8.7) 0.9

West Pacific 1,701,689 257,868 (17.6) 409 (1.0) 0.2

Page 11: 18581

0

500,000

1,000,000

1,500,000

2,000,000

2,500,000

3,000,000

Worldwide Africa Asia

Estimated World and Regional Malaria Deaths, 1952-1999

Page 12: 18581

Disease

Malaria 57.9%

Childhood Diseases 55.0%

Diarrheal Diseases 53.2%

Perinatal Conditions 45.0%

Tuberculosis 44.4%

Maternal Conditions 43.2%

Respiratory Infections 42.6%

HIV/AIDS 41.8%

Weighted Average 48.6%

Percentage of Deaths from Disease OccurringAmong the Poorest 20% of Global Population

% Deaths

Page 13: 18581

Interventions

Page 14: 18581

Estimated Cost of Malaria Control in an Endemic Area: One Million People, One Round

of Residual House Spraying

Insecticide

One application (tons) Price/ton Total cost

Cost per capita

DDT 147 $3,950 $580,650 $0.58

Malathion 220 $4,300 $946,000 $0.95

Deltamethrin 110 $20,000 $2,200,000 $2.20

Pyrimiphos-methyl

220 $16,000 $3,520,000 $3.52

Page 15: 18581

Estimated Cost of Malaria Control: One Million People, One Full-dose Treatment, 1999

Drug

Tablets in millions (dose)

Price/ 1000 tabs Total cost

Cost per

capita

Chloroquine (3 days)

11.25 (100 mg)

$6.05 $68,063 $0.08

Sulfadoxine-pyrimethamine (one dose)

2.5 (500 mgS/

25 mgP)

$47.00 $117,500 $0.12

Quinine (7 d) 31.5 (300 mg) $41.25 $1,299,375 $1.30

Artesunate (5 d) 13.5 (50 mg) $365.00 $4,927,500 $4.93

Page 16: 18581

Successes

Page 17: 18581

• 1899, (large scale) demonstration of successful Anopheline control in Cuba: antilarval and adult measures (large-scale)

• 1899–1914, multiple demonstrations of control by reduction of Anopheline larvae and adults– 1899, Sierra Leone (antilarval); Cuba (large-scale);

Malaysia (antilarval)– 1904–1914, Panama Canal Zone; control by

larviciding, large-scale environmental modification

• 1927, elimination of A. albimanus in Barbados (first area-wide success with invading species)

Successes

Page 18: 18581

Successes (2)

• 1935-1939, large-scale control by pyrethrum spraying in South Africa, Netherlands and India

• 1939-1957– 1939-1940, Elimination of invading A.gambiae

from Brazil– 1942-1945, A.gambiae eliminated from

northern Egypt– 1946-1957, Interruption of transmission by

anti-mosquito measures in Cyprus, Sandinia, Guyana, Venezuela and Greece; indoor residual spraying with DDT, a major strategy

Page 19: 18581

Successes (3)

• 1987-2003– Multiple projects and programs using

insecticide-impregnated bed nets demonstrate overall mortality reduction and decrease in several malaria indices

Page 20: 18581

Interventions, Control and Economics

Page 21: 18581

Type of ControlVector Control

• Environmental modification (urban)*• Chemical and biological larvicides*• Indoor residual insecticide spraying*• Outdoor residual insecticide spraying

*costly and effective

Page 22: 18581

Type of ControlPersonal protection (2)

• Insecticide–impregnated materials:

nets, curtains, clothing*

• House screening

• House location

• Repellents

• Fumigants

* Shown cost effective for low-income countries

Page 23: 18581

Type of ControlAntiplasmodial (3)

• Patient management: early diagnosis, treatment, referral, education

• Chemoprophylaxis• Intermittent treatment (pregnancy)*• Radical therapy for relapses (P.vivax,

P.ovale)

* cost effective

Page 24: 18581

Type of ControlSocial Action

• Mobilization of individual, family, community• Health education

Management Effectiveness• Health systems effectiveness (quality),

efficiency• Leadership, planning, policies, strategies,

tactics• Surveillance• Monitoring and evaluation

Page 25: 18581

Research Questions

Page 26: 18581

Research Agenda

• Pathogenesis

• Drug development

• Vaccine development

• Diagnostics

• Clinical and community-based trials

• Entomology

Page 27: 18581

Research Agenda (2)

• Clinical issues– anemia– neurologic and cognition– pregnancy-related

• Health services delivery

• Social, legal, ethical

Page 28: 18581

Controversies

Page 29: 18581

Controversies

• Drugs– Combination artemisinin-based

compounds for treatment– Chemoprophylaxis for high risk persons

• Burden– Malaria as a cause or risk-factor

(co-morbidity)– Cognition and developmental issues

Page 30: 18581

Controversies (2)

• Transmission– Cost-effective vector control

approaches in urban and rural areas– Impregnated materials, how to improve

and make the social standard

• Basic research– Immunologic, genetic

Page 31: 18581

Malaria, Annual WHO Estimates, 1997

Region

Population at risk (1000s)

Total Cases

(%) (1000s)

P. Falciparum

(%) (1000s)

P.vivax

(%) (1000s)

SE Asia,

Western Pacific

1,284,000 86,401 44,400 42,006

Eastern Mediterranean

64,600 14,539 2,883 11,656

Central America/ Caribbean

64,200 3,676 580 3,096

South America 23,500 11,325 3,347 7,978

Central Asia/ Cancasus

8,480 167 0 167

World total outside Africa

1,444,780 116,334 51,211 65,124

Africa 550,000 300,000 Most of total 6-15,000

Imported malaria² 1,590,000 33 11 22

Total ³

Page 32: 18581

Malaria in Sri Lanka

0

100000

200000

300000

400000

500000

600000

1963 1968 1973 1978 1983 1988 1993

Year

Nu

mb

er o

f ca

ses

0

10

20

30

40

50

60

P.falcip

arum

as %

of to

tal malaria

DDT spraying

ends

First report of chloroquine

resistant P.falciparum

Plasmodium falciparum

Plasmodium vivax

Page 33: 18581

0.01

0.10

1.00

0.000 0.001 0.010 0.100 1.000 10.000

Annual malaria incidence rate (%)

Pro

po

rtio

n o

f P

.viv

ax

: :

% P

lasm

od

ium

viv

ax100

10

1

Total Annual Malaria Incidence Rate (%)

0.000 0.01 0.001 0.1 1.0 10.0

Page 34: 18581

0.01

0.10

1.00

0.000 0.001 0.010 0.100 1.000 10.000

Annual malaria incidence rate (%)

Pro

po

rtio

n o

f P

.viv

ax

: :

% P

lasm

od

ium

viv

ax100

10

1

0.000 0.01 0.001 0.1 1.0 10.0 More Northerly, more temperate

More Southerly, more tropical